The LiBBY findings do not change care for mild cognitive impairment because the trial studied a different group. It tested hospice-eligible people with late-stage dementia and agitation, not people with early memory changes who still manage daily life.
Mild cognitive impairment, or MCI, means measurable thinking changes with largely preserved independence. Agitation in this context means restlessness, verbal outbursts, or physical behaviors tied to distress. LiBBY tested a specific prescription approach for severe, late-stage agitation under close home supervision.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the LiBBY trial test?
- How large was the agitation benefit?
- Why do the results not apply to MCI?
- What limits safety and access?
- What can families facing MCI do now?
What did the LiBBY trial test?
LiBBY, short for Life's End Benefits of cannaBidiol and tetrahYdrocannabinol, was a 12-week Phase 2 trial in 120 hospice-eligible adults with late-stage Alzheimer's or other dementias. The Alzheimer's Association presentation at AAIC 2026 in London described randomization to purified oral THC/CBD or placebo alongside usual care, detailed in the Association's trial summary. Participants received a digestible-oil product twice daily across 10 U.S. sites with home visits.
Dosing began low in week one, then increased for the rest of the trial. Usual medical and comfort care continued. The treatment was not dispensary cannabis. It was a controlled, purified oil made for research use only.
How large was the agitation benefit?
The THC/CBD group had a larger drop on the Cohen-Mansfield Agitation Inventory at week two. That scale rates restlessness, shouting, hitting, pacing, and related behaviors. The benefit persisted through week 12.
Clinicians also rated overall improvement much higher on active treatment both early and late. Medical University reporting via MIMS described the week-two inventory change as −10.61 points versus −4.35 on placebo, described in the MIMS trial report. These were short-term results in a small sample. Larger trials would be needed before regulators could consider approval.
Why do the results not apply to MCI?
MCI and late-stage dementia differ in diagnosis, function, and care goals. MCI involves early cognitive change with mostly independent daily activities. LiBBY required major neurocognitive disorder plus hospice and functional-severity thresholds. Agitation also differs by stage.
In late dementia, it often reflects pain, confusion, unmet needs, or communication loss near the end of life. In MCI, distress more often involves worry about memory, sleep loss, depression, medications, or medical illness. A treatment that calms severe late-stage agitation does not show safer thinking, slower decline, or better daily function in MCI. Readers with MCI need prevention, monitoring, and treatable-cause care, not end-of-life agitation treatment.
What limits safety and access?
Overall adverse events were similar, but serious events were more common with THC/CBD. NeurologyLive reported serious adverse events in 23.3% versus 11.9% on placebo, driven by serious infections, with more deaths on active treatment that investigators judged unrelated to study drug, reported in the NeurologyLive safety summary. That pattern matters because hospice-eligible patients already face high illness and infection risk. THC can also cause sedation, confusion, falls, and drug interactions.
CBD can affect liver enzymes and other medicines. Access is another limit. The T2:C100 oil is a proprietary investigational product and is not sold or FDA-approved. Families should not substitute store, dispensary, or online cannabis at these doses.
What can families facing MCI do now?
Focus on current, proven steps for brain health and daily safety. Review sleep, mood, hearing, vision, blood pressure, diabetes, alcohol, and sedating medicines with the primary-care clinician.
For active agitation in dementia, guidelines still start with calm routines, pain control, and simple surroundings. Approved medicines, including brexpiprazole for Alzheimer's agitation, are clinician decisions after weighing benefits and risks. Bring the trigger diary and medication list to the visit and ask which non-drug plan fits first.
- Track memory lapses, daily tasks, driving safety, and missed bills for two to four weeks
- List all drugs, supplements, sleep aids, pain medicines, and cannabis products
- Note agitation triggers: pain, hunger, thirst, noise, change, fatigue, infection
- Ask about counseling, exercise, hearing care, and caregiver support referrals
You Might Also Like
- AAIC 2026 PROTECT-Cog Lifestyle and GLP-1 Trial: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
- Medication Safety and Deprescribing in WHO’s 2026 Delirium Work: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
